Compare Kimberly Clark Corp (KMB) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Novartis AG — how do they compare? Kimberly Clark Corp trades at $108.01 (market cap $36.01B), while Novartis AG trades at $154.94 (market cap $290.25B). The key difference: Novartis AG is far larger — about 8.1× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| KMB | NVS | |
|---|---|---|
Market Cap | $36.01B | $290.25B |
Sector | Consumer Staples | Health |
52-Week High | $136.77 | $168.62 |
52-Week Low | $93.05 | $113.50 |
Enterprise Value | $42.55B | $330.27B |
Dividend Yield | 4.72% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $108.43, up 0.07% on the day, with a neutral technical signal and bullish moving averages. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.97 exceeding the $1.93 estimate. Revenue declined to $16.45B in 2025, but net income margin remains strong at 12.8%. Recent news highlights KMB's innovation strategy and its status as a Dividend King, with a 4.5% yield attracting income investors.
KMB offers stable income with a high dividend yield and solid fundamentals, but faces revenue pressure and competitive risks. Analyst consensus is a $115.33 price target with a hold-heavy rating. Key risks include consumer sentiment impacts and input cost inflation, while the pending Kenvue merger provides growth potential.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
